Loading…
Loading…
Chongqing's General Office of the municipal government published Yu Fu Ban Fa [2025] No. 56 on 2025-11-01 (fast-tracked to the public gazette 2025-11-10), a 25-measure package covering the full innovative-drug development chain: R&D incentives, clinical-trial acceleration, registration fast-tracking, medical-insurance payment support, and financing support for innovative-drug enterprises.
Concrete operational commitments include:
processed within 15 working days.
ethics review and application processing run in parallel rather than sequentially.
listed innovative drugs — i.e. no exclusion via drug-budget caps or formulary ratios, guaranteeing a de facto procurement floor.
Priority disease areas: malignant tumors, metabolic disease, autoimmune disease, cardiovascular/cerebrovascular disease, infectious disease, CNS disease, and rare disease.
Targets: 1-3 newly approved innovative drugs annually through 2027 (10 cumulative), plus 3 pharmaceutical-innovation industrial complexes, 3 high-level innovation platforms, and 3 innovative-drug industry clusters.
GTA classifies this as "State aid, unspecified" (Red) across eight separate implementation dates (2025-12-01 through 2025-12-30) tied to the same state act, with a nominal 2028-11-30 revocation/review date — consistent with a multi-tranche rollout of the same policy package rather than eight distinct measures.
Severity is set at 2 (qual) because the published text discloses no direct subsidy amount, tax credit, or fund size — the support is procedural/market-access (registration speed, procurement guarantee) rather than a quantified fiscal transfer. This is one of several 2025 Chinese sub-national biopharma industrial-policy packages (Shanghai Huangpu translational-medicine and BCI subsidies, Beijing medical-device support measures) filed under the same strategic-emerging-industries theme.
innovative-drug clusters, following similar Shanghai and Beijing packages filed in the same window.
meaningful non-tariff market-access lever for domestic biopharma firms versus imported innovative drugs, even without a disclosed subsidy figure.
(R&D tax credits, direct grants, or a dedicated fund) — the current text is procedural only.
fiscal-support document exists or is forthcoming.
for specific named companies (none disclosed in the primary source).